# Roflumilast and Cognition

> **NCT01433666** · PHASE2 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** roflumilast (EU: Daxas, USA: Daliresp)
- **DRUG:** Placebo
- **DRUG:** roflumilast

## Key facts

- **NCT ID:** NCT01433666
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-07
- **Final completion:** 2013-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433666, "Roflumilast and Cognition". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01433666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*